ACADIA Pharmaceuticals Inc. ACAD

ACAD Company Overview

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders. The company operates within the biotechnology and pharmaceuticals industries, with a primary emphasis on neurological and psychiatric conditions that have significant unmet medical needs. ACADIA’s core revenue driver is its approved CNS-focused pharmaceutical products, supported by ongoing research and development activities aimed at expanding indications and advancing new drug candidates.

The company’s primary commercial product is NUPLAZID® (pimavanserin), approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA primarily serves neurologists, psychiatrists, and institutional healthcare providers, positioning itself as a specialized CNS innovator. Founded in 1993, the company initially pursued broader neuroscience research before strategically narrowing its focus to CNS disorders, evolving into a commercial-stage biopharmaceutical company following regulatory approval of NUPLAZID in 2016.